JP2010530846A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530846A5
JP2010530846A5 JP2010510365A JP2010510365A JP2010530846A5 JP 2010530846 A5 JP2010530846 A5 JP 2010530846A5 JP 2010510365 A JP2010510365 A JP 2010510365A JP 2010510365 A JP2010510365 A JP 2010510365A JP 2010530846 A5 JP2010530846 A5 JP 2010530846A5
Authority
JP
Japan
Prior art keywords
peptide
mol
reducing sugar
reducing
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010510365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530846A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/006898 external-priority patent/WO2008150479A2/en
Publication of JP2010530846A publication Critical patent/JP2010530846A/ja
Publication of JP2010530846A5 publication Critical patent/JP2010530846A5/ja
Pending legal-status Critical Current

Links

JP2010510365A 2007-06-01 2008-05-29 高温で安定なペプチド製剤 Pending JP2010530846A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94155607P 2007-06-01 2007-06-01
US96908007P 2007-08-30 2007-08-30
PCT/US2008/006898 WO2008150479A2 (en) 2007-06-01 2008-05-29 High temperature stable peptide formulation

Publications (2)

Publication Number Publication Date
JP2010530846A JP2010530846A (ja) 2010-09-16
JP2010530846A5 true JP2010530846A5 (enExample) 2012-07-19

Family

ID=40094334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010510365A Pending JP2010530846A (ja) 2007-06-01 2008-05-29 高温で安定なペプチド製剤

Country Status (7)

Country Link
US (1) US7879805B2 (enExample)
EP (1) EP2150537A4 (enExample)
JP (1) JP2010530846A (enExample)
AU (1) AU2008260483A1 (enExample)
CA (1) CA2687246A1 (enExample)
MX (1) MX2009012964A (enExample)
WO (1) WO2008150479A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2350649A4 (en) * 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
TWI548414B (zh) * 2009-11-23 2016-09-11 庫比斯特製藥有限責任公司 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
HUE042330T2 (hu) * 2010-03-31 2019-06-28 Stabilitech Biopharma Ltd Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására
EP2898890B1 (en) 2010-03-31 2019-08-21 Stabilitech Biopharma Ltd Stabilisation of viral particles
HUE033656T2 (en) 2010-03-31 2017-12-28 Stabilitech Ltd Binders for stabilizing virus particles
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
CN102488886B (zh) * 2011-09-26 2014-03-26 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN103386117B (zh) * 2011-09-26 2015-09-30 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US20140287995A1 (en) * 2011-11-02 2014-09-25 The University Of Chicago Stable pharmaceutical formulations of growth factor peptides
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6148487B2 (ja) * 2012-05-31 2017-06-14 久保木　芳徳 チタン−タンパク質複合体の製造方法
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
DK3149048T3 (en) * 2014-05-28 2020-04-14 Nono Inc Chloridsalt af tat-nr2b9c
SG10201902598VA (en) * 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN109528761A (zh) * 2018-12-20 2019-03-29 江西润泽药业有限公司 制备钠钾钙镁葡萄糖注射液的方法
WO2021183752A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11534528B2 (en) * 2020-03-31 2022-12-27 3-D Matrix, Ltd. Sterilization of self-assembling peptides by irradiation
KR102869156B1 (ko) * 2021-03-29 2025-10-15 (주)아모레퍼시픽 콜라겐 펩티드 안정화용 조성물 및 이를 포함하는 식품

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
JP2003055257A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第ｘｉｉｉ因子製剤
EP1503767A2 (en) * 2002-02-08 2005-02-09 ACOLOGIX, Inc. Compositions and methods for treatment of vitamin d deficiency
EP1556091A1 (en) * 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
EP1778723B1 (en) * 2004-08-17 2012-11-14 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations

Similar Documents

Publication Publication Date Title
JP2010530846A5 (enExample)
JP2007262090A5 (enExample)
JP2011506530A5 (enExample)
JP2011088897A5 (enExample)
JP2010534684A5 (enExample)
WO2011008548A8 (en) Vaccines and compositions against streptococcus pneumoniae
JP2013510216A5 (enExample)
TWD123746S1 (zh) 繃帶
WO2009048148A1 (ja) シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤
JP2013507408A5 (enExample)
JP2011528897A5 (enExample)
JP2011526526A5 (enExample)
JP2012516348A5 (enExample)
WO2008069911A3 (en) Dual composition with warming and analgesic effects
JP2012500946A5 (enExample)
JP2006342148A5 (enExample)
JP2009242695A5 (enExample)
JP2010030903A5 (enExample)
WO2010098625A3 (ko) 약제학적 제제
Yip Eco-city: From Concept to Implementation-Case Studies in Shanghai Dongtan and Beijing Changxindian
JP2007119348A5 (enExample)
Levine Today is a new day
JP2007145829A5 (enExample)
Sapna Small-Pox: Remedies and diagnosis
夏增强 Reflections On Christianity